AUM Biosciences
Business Services · Maryland, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
7265 Wisconsin Ave, Bethesda, Maryland, ...Phone Number
+65 68086034Website
www.aumbiosciences.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About AUM Biosciences
AUM Biosciences is a global clinical stage biotech company that was founded in 2018. AUM is focused on discovering and developing novel targeted oncology therapies, particularly for cancers with a clear genetic marker.Explore more
AUM Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AUM Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at AUM Biosciences
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if AUM Biosciences is spiking on competitors!
Check if AUM Biosciences has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once AUM Biosciences has new funding data
Click to see if AUM Biosciences had a recent Job posting/layoffs
Product Launch: Get notified when AUM Biosciences launches new products
Earning: See what the market has to say on AUM Biosciences recently announced quarterly report
AUM Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to AUM Biosciences
Compare insights from companies similar to AUM Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
AUM Biosciences is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
AUM Biosciences is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about AUM Biosciences.
AUM Biosciences financials insights
Gather financial insights about AUM Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Angel/Seed
$1.5M
2021
Series A
$27M
AUM Biosciences Tech Stack
A closer look at the technologies used by AUM Biosciences
See more technologies
Most Recent Scoops
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Funding
New Hire
Executive Move
Dave Harish has been named Chief Medical Officer & Executive Director.
Executive Moves, New Hire, Personnel Moves
New Hire
Executive Move
AUM Biosciences News & Media
AUM Biosciences to Participate in Inaugural EF Hutton Global Conference
SINGAPORE and BETHESDA, Md., April 26, 2023 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotechnology company focused on advancing a pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance, announced today that the management team will participate in the Inaugural EF Hutton Global Conference (the “Conference”) in New York, New York from May 10th to May 11th. The AUM management team will hosAUM Biosciences Receives U.S. FDA Rare Pediatric Disease Designation for AUM302 for Treatment of Neuroblastoma
AUM302 is potentially eligible to receive a rare pediatric disease priority review voucher at the time of marketing approval AUM302 is potentially eligible to receive a rare pediatric disease priority review voucher at the time of marketing approvalAUM Biosciences Receives FDA Orphan Drug Designation for AUM302 for the Treatment of Neuroblastoma
AUM302 has potential to be the first multi-kinase inhibitor class of drug in Neuroblastoma AUM302 has potential to be the first multi-kinase inhibitor class of drug in NeuroblastomaAUM Biosciences Receives Human Research Ethics Committee Approval to Commence Phase II Clinical Trial of AUM001 for Treatment of Metastatic Colorectal Cancer in Australia
SINGAPORE and BETHESDA, Md., Nov. 15, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a clinical-stage biotechnology company, advancing a clinical stage candidate and a broader pipeline designed to deploy multi-faceted inhibition strategies to reverse cancer resistance, today announced it has received Human Research Ethics Committee (“HREC”) approval to commence a Phase II clinical trial of its selective translation inhibitor AUM001 in Australia. Ethics approval is confirmation that
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AUM Biosciences
Sign Up For FreeTo access detailed company insights
AUM Biosciences is a global clinical stage biotech company that was founded in 2018. AUM is focused on discovering and developing novel targeted oncology therapies, particularly for cancers with a clear genetic marker.... Read More
